Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Leveraging the germ layer development patterns to predict prognosis and identify MEST as a novel therapeutic target in glioma.

  PMID 41501725 · PMC12870398 · Cancer cell international · 2026 · 7 claims · 8 setups

  Full-text index only

  MEST is a key oncogenic GLD-related gene and a novel therapeutic target in glioma, identified via a machine learning feature selection framework

  bulk single-cell tcga glioma gsva aucell machine

• Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.

  PMID 41735308 · PMC13043769 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  OSGEP is the catalytic subunit of the KEOPS complex responsible for t6A modification at position 37 of cytoplasmic tRNAs, and its loss causes the highest protein aggregation among 45 screened tRNA-modifying enzymes in melanoma cells

  mm117 b16f10 b16f10-derived c57bl esirna shrna rna-seq

• Aging-associated differences in mammary tumor-initiating populations and immune evasion pathways in breast cancer.

  PMID 41719331 · PMC12933083 · Proceedings of the National Academy of Sciences of the United States of America · 2026 · 8 claims · 8 setups

  Full-text index only

  Age at NMU exposure critically influences tumor incidence, mutational burden, molecular subtype, and the tumor immune microenvironment

  virgin mammary tcga-brca carcinogen-induced immunofluorescence bulk

• Targeting KIFC1 to disrupt centrosome clustering and trigger anaphase catastrophe in small-cell lung cancer.

  PMID 41948931 · PMC13134724 · JCI insight · 2026 · 8 claims · 8 setups

  Full-text index only

  KIFC1 is overexpressed in SCLC compared with normal tissues and other cancer types

  sclc h146 clinical cancer immunofluorescence viability flow